Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD

about

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD

Item

http://www.wikidata.org/entity/Q37120706

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD

@en

Role of once-daily glycopyrronium bromide

@nl

type

Item

label

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD

@en

Role of once-daily glycopyrronium bromide

@nl

prefLabel

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD

@en

Role of once-daily glycopyrronium bromide

@nl

P1476

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD

@en

P2093

Anthony D'Urzo

http://www.w3.org/2001/XMLSchema#string

P2860

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.

P304

341-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S30317

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256291734

http://www.w3.org/2001/XMLSchema#string

P698

23990727

http://www.w3.org/2001/XMLSchema#string

P932

3753168

http://www.w3.org/2001/XMLSchema#string